Tag: #oncology

Articles related to oncology

health

FDA Grants Accelerated Approval to Rybrevant Faspro for Recurrent, Metastatic Head and Neck Cancer

FDA grants accelerated approval to Janssen's Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma after chemo and immunotherapy.

#oncology, #fda, #drugapproval, #headandneck, #janssen

health

FDA Expands Approval of Talzenna Plus Xtandi for HRR‑Mutated Metastatic Castration‑Sensitive Prostate Cancer

FDA on Oct. 26 approved Talzenna plus Xtandi for HRR‑mutated metastatic castration‑sensitive prostate cancer; genetic testing required.

$PFE, #fda, #prostatecancer, #oncology, #pfizer

health

NHS launches pilot of rapid genomic test to cut brain tumour diagnosis from weeks to days

NHS England is piloting a rapid genomic test for brain tumours in five specialist centres, aiming to shorten diagnosis from weeks to days.

#nhs, #genomics, #brain-tumour, #diagnostics, #oncology

health

Durvalumab Plus FLOT Boosts Survival in Resectable Gastric and GEJ Cancer, MATTERHORN Shows

Phase 3 MATTERHORN shows AstraZeneca’s durvalumab added to perioperative FLOT improves overall and event‑free survival in resectable gastric/GEJ cancer.

$AZN, #oncology, #immunotherapy, #durvalumab, #gastric-cancer, #astrazeneca

health

FDA Approves Rasonque (daraxonrasib), First Targeted Therapy for Most Common Form of Metastatic Pancreatic Cancer

FDA cleared Rasonque for adults with previously treated metastatic pancreatic adenocarcinoma after a Phase 3 trial showed a significant overall survival benefit.

$RVMD, #health, #pancreaticcancer, #oncology, #drugapproval

health

FDA Grants Accelerated Approval to Replimune’s Tudriqev for PD-1–Resistant Advanced Melanoma

FDA gives accelerated approval to Replimune’s Tudriqev with nivolumab for adults with PD‑1–resistant unresectable advanced melanoma; confirmatory trials required.

$RPLM, #melanoma, #fda, #oncology, #replimune, #drugapproval

health

FDA Expands IBRANCE Approval for Maintenance Treatment in HR+, HER2+ Metastatic Breast Cancer

FDA expands use of Pfizer’s IBRANCE (palbociclib) as maintenance therapy with trastuzumab and endocrine therapy for HR+, HER2+ metastatic breast cancer.

$PFE, #oncology, #breastcancer, #fda, #pharma

health

Pfizer’s Phase 3 Lung Cancer Drug Misses Overall Survival Goal; Stronger Trend in Second‑Line Patients

Pfizer's Phase 3 lung cancer trial of sigvotatug vedotin missed its overall survival goal; company sees a stronger trend in second‑line patients.

$PFE, #pfizer, #oncology, #lungcancer, #clinicaltrials

health

Pfizer’s BRAFTOVI Combo Shows Longer Progression-Free Survival in First-Line BRAF V600E Metastatic Colorectal Cancer

Phase 3 BREAKWATER Cohort 3 data show encorafenib plus cetuximab with FOLFIRI extended median PFS to 15.2 months vs. 8.3 months in control.

$PFE, #oncology, #colorectalcancer, #pfizer, #braftovi